Relationship between cerebral sigma-1 receptor occupancy and attenuation of cocaine's motor stimulatory effects in mice by PD144418

Journal of Pharmacology and Experimental Therapeutics

Volumn 351, Issue 1, 2014, Pages 153-163

  Lever, John R ^a,b   Miller, Dennis K ^b,c   Fergason Cantrell, Emily A ^a,b   Green, Caroline L ^c   Watkinson, Lisa D ^a,b   Carmack, Terry L ^a,b   Lever, Susan Z ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b University of Missouri   (United States)

^c UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 5 [3 (4 METHYLPHENYL) 5 ISOXAZOLYL] 1 PROPYLPYRIDINE; COCAINE; DOPAMINE TRANSPORTER; NORADRENALIN TRANSPORTER; OPIATE ANTAGONIST; SEROTONIN TRANSPORTER; SIGMA 1 OPIATE RECEPTOR; SIGMA 2 OPIATE RECEPTOR; UNCLASSIFIED DRUG; 1-PROPYL-5-(3-P-TOLYLISOXAZOL-5-YL)-1,2,3,6-TETRAHYDROPYRIDINE; ISOXAZOLE DERIVATIVE; NARCOTIC ANTAGONIST; PROTEIN BINDING; PYRIDINE DERIVATIVE; SIGMA OPIATE RECEPTOR; SIGMA-1 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG PROTEIN BINDING; HYPERACTIVITY; IN VITRO STUDY; IN VIVO STUDY; LOCOMOTION; MALE; MOUSE; NONHUMAN; RECEPTOR OCCUPANCY; SINGLE DRUG DOSE; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMISTRY; DRUG EFFECTS; GUINEA PIG; HYPERKINESIA; METABOLISM; MOTOR CORTEX;

ANIMALS; BINDING SITES; COCAINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; GUINEA PIGS; HYPERKINESIS; ISOXAZOLES; LOCOMOTION; MALE; MICE; MOTOR CORTEX; NARCOTIC ANTAGONISTS; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PROTEIN BINDING; PYRIDINES; RECEPTORS, SIGMA; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 84907164798     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.216671     Document Type: Article

References (35)

1. Akunne HC, Whetzel SZ, Wiley JN, Corbin AE, Ninteman FW, Tecle H, Pei Y, Pugsley TA, and Heffner TG (1997) The pharmacology of the novel and selective sigma ligand, PD 144418. Neuropharmacology 36:51-62.
2. Boja JW, Cadet JL, Kopajtic TA, Lever J, Seltzman HH, Wyrick CD, Lewin AH, Abraham P, and Carroll FI (1995) Selective labeling of the dopamine transporter by the high affinity ligand 3 b-(4-[125I]iodophenyl)tropane-2 b-carboxylic acid isopropyl ester. Mol Pharmacol 47:779-786.
3. Bouchard P, Roman F, Junien J-L, and Quirion R (1996) Autoradiographic evidence for the modulation of in vivo sigma receptor labeling by neuropeptide Y and calcitonin gene-related peptide in the mouse brain. J Pharmacol Exp Ther 276: 223-230.
4. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
5. Cobos EJ, Baeyens JM, and Del Pozo E (2005) Phenytoin differentially modulates the affinity of agonist and antagonist ligands for s 1 receptors of guinea pig brain. Synapse 55:192-195.
6. DeHaven-Hudkins DL, Fleissner LC, and Ford-Rice FY (1992) Characterization of the binding of [3H](1)-pentazocine to sigma recognition sites in guinea pig brain. Eur J Pharmacol 227:371-378.
7. Desai RI, Kopajtic TA, French D, Newman AH, and Katz JL (2005) Relationship between in vivo occupancy at the dopamine transporter and behavioral effects of cocaine, GBR 12909 [1-2-[bis-(4-fluorophenyl)methoxy]ethyl-4-(3-phenylpropyl) piperazine], and benztropine analogs. J Pharmacol Exp Ther 315:397-404.
8. Garcés-Ramírez L, Green JL, Hiranita T, Kopajtic TA, Mereu M, Thomas AM, Mesangeau C, Narayanan S, McCurdy CR, and Katz JL, et al. (2011) Sigma receptor agonists: receptor binding and effects on mesolimbic dopamine neurotransmission assessed by microdialysis. Biol Psychiatry 69:208-217.
9. Gifford AN, Bruneus M, Gatley SJ, Lan R, Makriyannis A, and Volkow ND (1999) Large receptor reserve for cannabinoid actions in the central nervous system. J Pharmacol Exp Ther 288:478-483.
10. Gund TM, Floyd J, and Jung D (2004) Molecular modeling of s1 receptor ligands: a model of binding conformational and electrostatic considerations. J Mol Graph Model 22:221-230.
11. Hall FS, Li XF, Randall-Thompson J, Sora I, Murphy DL, Lesch KP, Caron M, and Uhl GR (2009) Cocaine-conditioned locomotion in dopamine transporter, norepinephrine transporter and 5-HT transporter knockout mice. Neuroscience 162: 870-880.
12. Hirano K, Kimura R, Sugimoto Y, Yamada J, Uchida S, Kato Y, Hashimoto H, and Yamada S (2005) Relationship between brain serotonin transporter binding, plasma concentration and behavioural effect of selective serotonin reuptake inhibitors. Br J Pharmacol 144:695-702.
13. Hulme EC and Trevethick MA (2010) Ligand binding assays at equilibrium: validation and interpretation. Br J Pharmacol 161:1219-1237.
14. Kaushal N, Robson MJ, Vinnakota H, Narayanan S, Avery BA, McCurdy CR, and Matsumoto RR (2011) Synthesis and pharmacological evaluation of 6-acetyl-3- (4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79), a cocaine antagonist, in rodents. AAPS J 13:336-346.
15. Kovács KJ and Larson AA (1995) Discrepancies in characterization of s sites in the mouse central nervous system. Eur J Pharmacol 285:127-134.
16. Le S, Gruner JA, Mathiasen JR, Marino MJ, and Schaffhauser H (2008) Correlation between ex vivo receptor occupancy and wake-promoting activity of selective H3 receptor antagonists. J Pharmacol Exp Ther 325:902-909.
17. Lever JR, Scheffel U, Stathis M, Seltzman HH, Wyrick CD, Abraham P, Parham K, Thomas BF, Boja JW, and Kuhar MJ, et al. (1996) Synthesis and in vivo studies of a selective ligand for the dopamine transporter: 3 b-(4-[125I]iodophenyl) tropan-2 b-carboxylic acid isopropyl ester ([125I]RTI-121). Nucl Med Biol 23:277-284.
18. Lever JR, Gustafson JL, Xu R, Allmon RL, and Lever SZ (2006) s1 and s2 receptor binding affinity and selectivity of SA4503 and fluoroethyl SA4503. Synapse 59: 350-358.
19. Lever JR, Miller DK, Green CL, Fergason-Cantrell EA, Watkinson LD, Carmack TL, Fan K-H, and Lever SZ (2014) A selective sigma-2 receptor ligand antagonizes cocaine-induced hyperlocomotion in mice. Synapse 68:73-84.
20. Lever SZ, Xu R, Fan K-H, Fergason-Cantrell EA, Carmack TL, Watkinson LD, and Lever JR (2012) Synthesis, radioiodination and in vitro and in vivo sigma receptor studies of N-1-allyl-N'-4-phenethylpiperazine analogs. Nucl Med Biol 39: 401-414.
21. Matsumoto RR, Bowen WD, Tom MA, Vo VN, Truong DD, and De Costa BR (1995) Characterization of two novel sigma receptor ligands: antidystonic effects in rats suggest sigma receptor antagonism. Eur J Pharmacol 280:301-310.
22. Matsumoto RR, Liu Y, Lerner M, Howard EW, and Brackett DJ (2003) Sigma receptors: potential medications development target for anti-cocaine agents. Eur J Pharmacol 469:1-12.
23. Matsumoto RR, Nguyen L, Kaushal N, and Robson MJ (2014) Sigma (s) receptors as potential therapeutic targets to mitigate psychostimulant effects. Adv Pharmacol 69:323-386.
24. McCarthy LE, Mannelli P, Niculescu M, Gingrich K, Unterwald EM, and Ehrlich ME (2004) The distribution of cocaine in mice differs by age and strain. Neurotoxicol Teratol 26:839-848.
25. Menkel M, Terry P, Pontecorvo M, Katz JL, and Witkin JM (1991) Selective sigma ligands block stimulant effects of cocaine. Eur J Pharmacol 201:251-252.
26. Navarro G, Moreno E, Aymerich M, Marcellino D, McCormick PJ, Mallol J, Cortés A, Casadó V, Canela EI, and Ortiz J, et al. (2010) Direct involvement of s-1 receptors in the dopamine D1 receptor-mediated effects of cocaine. Proc Natl Acad Sci USA 107:18676-18681.
27. Ramsey SJ, Attkins NJ, Fish R, and van der Graaf PH (2011) Quantitative pharmacological analysis of antagonist binding kinetics at CRF1 receptors in vitro and in vivo. Br J Pharmacol 164:992-1007.
28. Robson MJ, Noorbakhsh B, Seminerio MJ, and Matsumoto RR (2012) Sigma-1 receptors: potential targets for the treatment of substance abuse. Curr Pharm Des 18:902-919.
29. Rodvelt KR, Lever SZ, Lever JR, Blount LR, Fan K-H, and Miller DK (2011) SA 4503 attenuates cocaine-induced hyperactivity and enhances methamphetamine substitution for a cocaine discriminative stimulus. Pharmacol Biochem Behav 97:676-682.
30. SageAS, Oelrichs CE,Davis DC, FanK-H, NahasRI, Lever SZ, Lever JR, andMillerDK (2013) Effects of N-phenylpropyl-N9-substituted piperazine sigma receptor ligands on cocaine-induced hyperactivity in mice. Pharmacol Biochem Behav 110:201-207.
31. Sora I, Li B, Igari M, Hall FS, and Ikeda K (2010) Transgenic mice in the study of drug addiction and the effects of psychostimulant drugs. Ann N Y Acad Sci 1187: 218-246.
32. Tejani-Butt SM, Brunswick DJ, and Frazer A (1990) [3H]nisoxetine: a new radioligand for norepinephrine uptake sites in brain. Eur J Pharmacol 191:239-243.
33. Wadenberg ML, Kapur S, Soliman A, Jones C, and Vaccarino F (2000) Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats. Psychopharmacology (Berl) 150:422-429.
34. Witkin JM, Terry P, Menkel M, Hickey P, Pontecorvo M, Ferkany J, and Katz JL (1993) Effects of the selective sigma receptor ligand, 6-[6-(4-hydroxypiperidinyl) hexyloxy]-3-methylflavone (NPC 16377), on behavioral and toxic effects of cocaine. J Pharmacol Exp Ther 266:473-482.
35. Xu YT, Kaushal N, Shaikh J, Wilson LL, Mésangeau C, McCurdy CR, and Matsumoto RR (2010) A novel substituted piperazine, CM156, attenuates the stimulant and toxic effects of cocaine in mice. J Pharmacol Exp Ther 333:491-500.